Face Name Associative Memory Exam--Greek Version

Extended FNAME performance is preserved in subjective cognitive decline but highly affected in amnestic mild cognitive impairment.

“…Notably, aMCI participants performed significantly worse than controls in all the associative memory abilities measured in the extended FNAME, as has been reported in previous studies Alviarez-Schulze et al, 2020;Kormas et al, 2020;Papp et al, 2014). Remembering the names of newly introduced face-name pairs was the most demanding task, reflected in the medium-to-large effect sizes of the recall subtests.…”

“…Unexpectedly, SCD subjects performed similarly well to controls in all subtests. This is in contrast to a worse performance of SCD in the delayed recall ability observed in a recent study using the nonextended FNAME (Kormas et al, 2020). Interestingly, the inclusion criteria for SCD were remarkably similar in both studies, except for one important aspect with implications to the understanding of SCD as a preclinical phase of AD.…”

“…In the present study, SCD participants were recruited by looking for older adults with memory complaints in nonclinical settings. In the study by Kormas et al (2020); however, SCD participants were recruited from a memory clinic, in which participants sought cognitive consultation. The This document is copyrighted by the American Psychological Association or one of its allied publishers.…”

“…FNAME performance in aMCI subjects has been found to be worse than clinically normal older adults and is correlated with other measures of episodic and semantic memory Papp et al, 2014). In a recent study, SCD subjects also displayed worse performance than older adult controls with normal performance on cognitive testing without memory complaints (CON) in FNAME delayed recall, which was even more affected in aMCI subjects (Kormas et al, 2020), which is consistent with a previous study using a face-name recognition computerized task (Polcher et al, 2017). Furthermore, FNAME performance correlates with β-amyloid and tau protein cerebrospinal fluid biomarkers (indicative of AD pathology) and cortical volumetric measurements in the right This document is copyrighted by the American Psychological Association or one of its allied publishers.…”